A Phase II Clinical Trial on Neo-adjuvant Pembrolizumab in Patients With pT3b-T4a/b cN0M0 Melanoma.

This study, called NeoSenti, is exploring whether giving one dose of the immunotherapy drug pembrolizumab before surgery can help the immune system fight melanoma more effectively. The study includes adults with high-risk melanoma who do not show any signs of the cancer having spread on scans. Participants receive a single infusion of pembrolizumab six weeks before their scheduled sentinel lymph node biopsy. The goal is to see if this early treatment can reduce or eliminate tiny cancer cells that might already be in the lymph nodes but are too small to detect. After surgery, patients whose me

Trial Details

NCT ID
NCT07448831
Phase
PHASE2
Sponsor
Universitair Ziekenhuis Brussel
Status
RECRUITING
Cancer Type
Melanoma
Locations (sample)
  • Jette, Brussels Capital, Belgium

Key Eligibility Criteria

  • ≥ 18 years of age on the day of signing the informed consent.
  • Histologically confirmed high risk primary cutaneous pT1b-4b melanoma High risk primary melanoma is defined in this study as the following AJCC8 T-…
  • pT1b-3a, with a poor prognostic score on the Merlin™ test ("Merlin™ high risk");
  • pT3b-4b, irrespective of their Merlin™ test result

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →